The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize

Virol Sin. 2018 Dec;33(6):467-471. doi: 10.1007/s12250-018-0077-3. Epub 2018 Dec 20.

Authors

Jia Liu¹, Wen Pan², Dongliang Yang²

Affiliations

¹ Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. jialiu77@hust.edu.cn.
² Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

No abstract available

Publication types

Historical Article

MeSH terms

Animals
Antibodies / therapeutic use
CTLA-4 Antigen / antagonists & inhibitors
Cell Cycle Checkpoints / drug effects
Cell Cycle Checkpoints / immunology*
Clinical Trials as Topic
History, 21st Century
Humans
Immunotherapy / history*
Immunotherapy / methods
Neoplasms / immunology
Neoplasms / therapy*
Nobel Prize
Programmed Cell Death 1 Receptor / antagonists & inhibitors
T-Lymphocytes / immunology
Virus Diseases / immunology
Virus Diseases / therapy*

Substances

Antibodies
CTLA-4 Antigen
PDCD1 protein, human
Programmed Cell Death 1 Receptor